Dolutegravir 25 MG Oral Tablet [Tivicay] — RxCUI 1796083
RxNorm drug concept · Semantic branded drug
RxCUI 1796083
Semantic branded drug · SBD
● Current RxNorm concept 4 FDA products
4 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1796083
Official nameDolutegravir 25 MG Oral Tablet [Tivicay]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asTivicay 25 MG (as dolutegravir sodium) Oral Tablet; Tivicay 25 MG Oral Tablet
FDA products mapped4
Package NDCs mapped4
Reported Medicaid activity (SDUD)95,552 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Dolutegravir: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Dolutegravir blocks a step HIV needs to survive inside your body. The virus uses an enzyme called integrase to insert its genetic code into your cells — once it does that, your cel...
- What exactly does dolutegravir do — how does it fight HIV?
- You can take dolutegravir with or without food — there's no strict requirement. That said, food does increase how much of the medicine your body absorbs, so taking it with a meal c...
- Can I take it with food, or does it have to be on an empty stomach?
🕸️ Concept Web — How Dolutegravir 25 MG Oral Tablet [Tivicay] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Dolutegravir 25 MG Oral Tablet [Tivicay]
RxCUI 1796083 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Dolutegravir
1433868IN
-
Dolutegravir
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Tivicay
1433874BN
-
Tivicay
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Dolutegravir Oral Tablet
1433872SCDF -
Dolutegravir Oral Product
1433870SCDG -
Dolutegravir Pill
1433871SCDG -
Dolutegravir Oral Tablet [Tivicay]
1433876SBDF -
Tivicay Oral Product
1433877SBDG -
Tivicay Pill
1433878SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Dolutegravir Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Dolutegravir 25 MG Oral Tablet
1796081SCD -
Dolutegravir 25 MG
1796080SCDC -
Dolutegravir 25 MG [Tivicay]
1796082SBDC
-
Dolutegravir 25 MG Oral Tablet
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Dolutegravir 25 MG Oral Tablet
SCD · 1796081 -
Dolutegravir 25 MG
SCDC · 1796080 -
Dolutegravir Oral Tablet
SCDF · 1433872 -
Dolutegravir Oral Product
SCDG · 1433870 -
Dolutegravir Pill
SCDG · 1433871
Brand-Name Concepts
-
Dolutegravir 25 MG [Tivicay]
SBDC · 1796082 -
Dolutegravir Oral Tablet [Tivicay]
SBDF · 1433876 -
Tivicay Oral Product
SBDG · 1433877 -
Tivicay Pill
SBDG · 1433878 -
Tivicay
BN · 1433874
📦 FDA Products & Package NDCs
4 products · 4 package NDCs
4 package NDCs map to RxCUI 1796083 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 49702-0226-13 | 30 TABLET, FILM COATED in 1 BOTTLE (49702-226-13) | Tivicay | ViiV Healthcare Company | 2016-06-09 |
| 49702-0227-13 | 30 TABLET, FILM COATED in 1 BOTTLE (49702-227-13) | Tivicay | ViiV Healthcare Company | 2016-06-09 |
| 49702-0228-13 | 30 TABLET, FILM COATED in 1 BOTTLE (49702-228-13) | Tivicay | ViiV Healthcare Company | 2013-08-13 |
| 49702-0255-37 | 1 BOTTLE in 1 CARTON (49702-255-37) / 60 TABLET, FOR SUSPEN... | Tivicay PD | ViiV Healthcare Company | 2020-06-12 |
Observed labelers:
ViiV Healthcare Company (4)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.